HUS000504I2 - Relebaktám, adott esetben monohidrát formájában, és imipenem kombinációja - Google Patents
Relebaktám, adott esetben monohidrát formájában, és imipenem kombinációjaInfo
- Publication number
- HUS000504I2 HUS000504I2 HUS2000024C HUS2000024C HUS000504I2 HU S000504 I2 HUS000504 I2 HU S000504I2 HU S2000024 C HUS2000024 C HU S2000024C HU S2000024 C HUS2000024 C HU S2000024C HU S000504 I2 HUS000504 I2 HU S000504I2
- Authority
- HU
- Hungary
- Prior art keywords
- relebactam
- imipenem
- monohydrate
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1153308P | 2008-01-18 | 2008-01-18 | |
EP09701487.2A EP2231667B1 (en) | 2008-01-18 | 2009-01-15 | Beta-lactamase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUS2000024I1 HUS2000024I1 (hu) | 2021-03-29 |
HUS000504I2 true HUS000504I2 (hu) | 2021-03-29 |
Family
ID=40642204
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS2000024C HUS000504I2 (hu) | 2008-01-18 | 2020-07-09 | Relebaktám, adott esetben monohidrát formájában, és imipenem kombinációja |
HUS2000023C HUS000513I2 (hu) | 2008-01-18 | 2020-07-09 | Relebaktám vagy monohidrátja |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS2000023C HUS000513I2 (hu) | 2008-01-18 | 2020-07-09 | Relebaktám vagy monohidrátja |
Country Status (39)
Country | Link |
---|---|
US (2) | US8487093B2 (hu) |
EP (2) | EP2231667B1 (hu) |
JP (3) | JP5038509B2 (hu) |
KR (2) | KR101800610B1 (hu) |
CN (2) | CN101918407B (hu) |
AU (1) | AU2009206119C1 (hu) |
BR (1) | BRPI0906871B1 (hu) |
CA (1) | CA2712783C (hu) |
CO (1) | CO6331438A2 (hu) |
CR (1) | CR11626A (hu) |
CY (5) | CY1114900T1 (hu) |
DK (2) | DK2231667T3 (hu) |
DO (1) | DOP2010000218A (hu) |
EC (2) | ECSP10010345A (hu) |
ES (2) | ES2433744T3 (hu) |
FR (3) | FR20C1031I2 (hu) |
HK (2) | HK1143809A1 (hu) |
HN (1) | HN2010001395A (hu) |
HR (2) | HRP20131123T1 (hu) |
HU (2) | HUS000504I2 (hu) |
IL (1) | IL206395A (hu) |
LT (3) | LTPA2020517I1 (hu) |
LU (1) | LUC00165I2 (hu) |
MA (1) | MA32025B1 (hu) |
ME (1) | ME02089B (hu) |
MX (1) | MX2010007823A (hu) |
MY (1) | MY162532A (hu) |
NI (1) | NI201000115A (hu) |
NL (2) | NL301051I2 (hu) |
NO (1) | NO2020024I1 (hu) |
NZ (1) | NZ586861A (hu) |
PL (2) | PL2666774T3 (hu) |
PT (2) | PT2231667E (hu) |
RS (2) | RS53862B1 (hu) |
RU (1) | RU2445314C9 (hu) |
SI (2) | SI2666774T1 (hu) |
UA (1) | UA101966C2 (hu) |
WO (1) | WO2009091856A2 (hu) |
ZA (1) | ZA201005333B (hu) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53862B1 (en) * | 2008-01-18 | 2015-08-31 | Merck Sharp & Dohme Corp. | INHIBITOR BETA-LACTAMASE |
PT2603514T (pt) | 2010-08-10 | 2018-11-09 | Rempex Pharmaceuticals Inc | Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas |
US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
CA2822758C (en) * | 2010-12-22 | 2018-03-20 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivative and process for preparing the same |
CA2780403C (en) * | 2011-06-17 | 2020-04-21 | Forest Laboratories Holdings Ltd. | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
MX348974B (es) * | 2011-08-27 | 2017-07-04 | Wockhardt Ltd | Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. |
RU2570423C2 (ru) | 2011-08-30 | 2015-12-10 | Вокхардт Лимитед | Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций |
WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
BR112014016804A8 (pt) | 2012-01-06 | 2017-07-04 | Univ California | composições, métodos de uso e métodos de tratamento |
US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
MX2014011825A (es) * | 2012-03-30 | 2015-02-20 | Cubist Pharm Inc | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. |
CA2868553A1 (en) * | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors |
US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
EP2847327B1 (en) | 2012-05-08 | 2018-12-26 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
BR112014029368B1 (pt) * | 2012-05-30 | 2020-10-27 | Meiji Seika Pharma Co., Ltd | inibidor de beta-lactamase e processo para preparar o mesmo |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
BR112015003592B1 (pt) * | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
EP2915805A4 (en) * | 2012-11-01 | 2016-03-23 | Kaneka Corp | METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLIC UREA COMPOUND |
PT2928898T (pt) | 2012-12-07 | 2021-07-05 | Venatorx Pharmaceuticals Inc | Inibidores de beta-lactamase |
UA111925C2 (uk) * | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA2894892A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA2894891A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
JP6285969B2 (ja) * | 2013-03-08 | 2018-02-28 | ウォックハート リミテッド | (2s,5r)−7−オキソ−6−スルホオキシ−2−[((3r)−ピペリジン−3−カルボニル)−ヒドラジノカルボニル]−1,6−ジアザ−ビシクロ[3.2.1]オクタンの調製のためのプロセス |
AU2013380573B2 (en) * | 2013-03-08 | 2016-07-07 | Wockhardt Limited | A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane |
KR101774132B1 (ko) | 2013-03-08 | 2017-09-01 | 욱크하르트 리미티드 | (2s, 5r)-7-옥소-6-술포옥시-2-[((3r)-피페리딘-3-카보닐)-히드라지노 카보닐]-1,6-디아자-비사이클로[3.2.1]-옥탄의 제조 방법 |
AU2013380575B2 (en) * | 2013-03-08 | 2016-07-07 | Wockhardt Limited | A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane |
RU2621051C2 (ru) * | 2013-03-08 | 2017-05-31 | Вокхардт Лимитед | Способ получения (2s, 5r)-моно-{ [(4-аминопиперидин-4-ил)карбонил]-7-оксо-1, 6-диазабицикло[3.2.1]окт-6-ил} ового сложного эфира серной кислоты |
WO2014135931A1 (en) * | 2013-03-08 | 2014-09-12 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane |
WO2014152996A1 (en) * | 2013-03-14 | 2014-09-25 | Cubist Pharmaceuticals, Inc. | Crystalline form of a beta-lactamase inhibitor |
WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
KR102265772B1 (ko) * | 2013-06-10 | 2021-06-15 | 머크 샤프 앤드 돔 코포레이션 | tert-부틸 4-((1R,2S,5R)-6-(벤질옥시)-7-옥소-1,6-디아자비시클로[3.2.1]옥탄-2-카르복스아미도)피페리딘-1-카르복실레이트의 제조 |
MY176278A (en) | 2013-09-24 | 2020-07-27 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative and intermediate thereof |
WO2015051101A1 (en) * | 2013-10-02 | 2015-04-09 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
EP3299370B1 (en) * | 2013-10-08 | 2021-11-24 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivative and production process thereof |
WO2015079329A2 (en) * | 2013-11-26 | 2015-06-04 | Wockhardt Limited | A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
PE20161371A1 (es) | 2014-03-24 | 2016-12-21 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas |
IN2014MU01196A (hu) * | 2014-03-29 | 2015-10-02 | Wockhardt Ltd | |
WO2015150891A1 (en) * | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-[2-(5-azetidin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo [3.2.1]oct-6-yl]ester |
DK3140310T3 (da) | 2014-05-05 | 2019-10-21 | Rempex Pharmaceuticals Inc | Syntese af boronatsalte og brug deraf |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
CA2947041A1 (en) | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP3882252A1 (en) | 2014-06-11 | 2021-09-22 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
HUE044061T2 (hu) * | 2014-11-17 | 2019-09-30 | Entasis Therapeutics Ltd | Kombinációs terápia rezisztens bakteriális fertõzések kezelésére |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
CN107428784B (zh) | 2014-12-02 | 2020-08-21 | 默沙东公司 | 用于制备4-((2s,5r)-6-(苄基氧基)-7-氧代-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺基)哌啶-1-甲酸叔丁酯及其类似物的方法 |
WO2016088863A1 (ja) | 2014-12-05 | 2016-06-09 | Meiji Seikaファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法 |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
TW201639853A (zh) * | 2015-03-31 | 2016-11-16 | 木塔比利斯公司 | 雜環化合物及其於預防或治療細菌感染之用途 |
CN107580595B (zh) * | 2015-05-07 | 2020-09-18 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
MX2017013792A (es) * | 2015-09-16 | 2018-07-06 | Xuanzhu Pharma Co Ltd | INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS. |
EA201890847A1 (ru) | 2015-10-02 | 2018-08-31 | Легокем Байосайенсез, Инк. | Композиции и способы ингибирования бета-лактамазы |
WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
KR20180094042A (ko) * | 2015-12-11 | 2018-08-22 | 욱크하르트 리미티드 | 7-옥소-6-(설포옥시)-1,6-디아자바이사이클로[3.2.1]옥탄-2-카르복사미드 함유 화합물 및 이의 세균 감염의 치료 용도 |
US10472345B2 (en) | 2016-02-04 | 2019-11-12 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
TW201736370A (zh) * | 2016-03-31 | 2017-10-16 | Xuanzhu Pharma Co Ltd | 一種抗菌組合物及其用途 |
EP3469088B1 (en) | 2016-06-09 | 2023-09-06 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
WO2018005662A1 (en) | 2016-06-30 | 2018-01-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
PL3512851T3 (pl) * | 2016-09-16 | 2022-11-14 | Entasis Therapeutics Limited | Związki stanowiące inhibitory beta-laktamazy |
US10464937B2 (en) * | 2016-09-19 | 2019-11-05 | Merck Sharp & Dohme Corp. | Process for preparing beta-lactamase inhibitor hydroxylurea intermediates |
JOP20190061A1 (ar) * | 2016-09-28 | 2019-03-26 | Novartis Ag | مثبطات بيتا-لاكتاماز |
CN108078982B (zh) * | 2016-11-21 | 2020-02-07 | 天津大学 | 脯氨酸衍生物在制备β-内酰胺酶抑制剂中的用途 |
CN117398398A (zh) | 2017-03-06 | 2024-01-16 | 云顶新耀新加坡有限公司 | 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 |
CN108619141B (zh) * | 2017-03-16 | 2021-09-10 | 山东轩竹医药科技有限公司 | 一种抗菌组合物及其用途 |
EA038393B1 (ru) | 2017-05-08 | 2021-08-20 | Энтасис Терапеутикс, Инк. | Соединения и способы для лечения бактериальных инфекций |
US10085999B1 (en) | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
AU2018304907B2 (en) | 2017-07-21 | 2022-11-24 | Antabio Sas | Chemical compounds |
CN109568323B (zh) * | 2017-09-29 | 2022-09-30 | 吉林四环制药有限公司 | 抗菌组合物及其用途 |
WO2019075084A1 (en) | 2017-10-11 | 2019-04-18 | Qpex Biopharma, Inc. | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF |
WO2019105479A1 (zh) | 2017-12-01 | 2019-06-06 | 南京明德新药研发股份有限公司 | 一种β-内酰胺酶抑制剂的晶型及其制备方法 |
CN109956941B (zh) * | 2017-12-25 | 2020-08-04 | 新发药业有限公司 | 一种阿维巴坦的简便制备方法 |
EP3744722A4 (en) | 2018-01-25 | 2021-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Ss-LACTAMASE INHIBITOR AND ITS USE |
EP3572411A1 (en) | 2018-05-21 | 2019-11-27 | Antabio SAS | Thiazole derivatives as metallo-beta-lactamase inhibitors |
WO2020030761A1 (en) * | 2018-08-09 | 2020-02-13 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
EP3670512A1 (en) * | 2018-12-18 | 2020-06-24 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
US11897844B2 (en) | 2018-09-21 | 2024-02-13 | Api Corporation | Method for producing amino acid derivatives |
CA3114618C (en) * | 2018-10-01 | 2023-09-05 | Arixa Pharmaceuticals, Inc. | Derivatives of relebactam and uses thereof |
CN111072660B (zh) * | 2018-10-22 | 2021-05-18 | 新发药业有限公司 | 一种瑞来巴坦的简便制备方法 |
SG11202108905UA (en) | 2019-03-12 | 2021-09-29 | Arixa Pharmaceuticals Inc | Crystalline form of an avibactam derivative |
WO2020219405A1 (en) * | 2019-04-26 | 2020-10-29 | Merck Sharp & Dohme Corp. | Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide |
WO2022047790A1 (en) * | 2020-09-07 | 2022-03-10 | Ningxia Academy Of Agriculture And Forestry Sciences | Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors |
CN111943950B (zh) * | 2020-09-10 | 2022-03-29 | 山东安信制药有限公司 | 一种瑞来巴坦的制备方法 |
US11814385B2 (en) * | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
WO2023220324A1 (en) * | 2022-05-11 | 2023-11-16 | The Regents Of The University Of Colorado A Body Corporate | Antibiotic composition and methods of use thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616038A (en) | 1978-07-24 | 1986-10-07 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
US5071843A (en) | 1978-07-24 | 1991-12-10 | Merck & Co., Inc. | Combination of 2-substituted carbapenems with dipeptidase inhibitors |
US4880793A (en) | 1978-07-24 | 1989-11-14 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
US4539208A (en) | 1980-09-17 | 1985-09-03 | Merck & Co., Inc. | Combination of thienamycin-type antibiotics with dipeptidase inhibitors |
EP0508234B1 (de) | 1991-04-11 | 1996-07-24 | F. Hoffmann-La Roche Ag | Beta-Lactame |
US5854239A (en) | 1993-12-29 | 1998-12-29 | Pfizer Inc. | Diazabicyclic neuokinin antagonists |
JP3199300B2 (ja) | 1994-05-09 | 2001-08-13 | 三共株式会社 | 1−メチルカルバペネム誘導体 |
CA2241092C (en) | 1995-12-21 | 2004-04-27 | Sankyo Company, Limited | 1-methylcarbapenem derivatives |
JP2965922B2 (ja) * | 1995-12-21 | 1999-10-18 | 三共株式会社 | 1−メチルカルバペネム誘導体 |
JP2955276B2 (ja) | 1997-06-19 | 1999-10-04 | 三共株式会社 | 1−メチルカルバペネム誘導体を含有する抗菌剤 |
JP4490517B2 (ja) | 1998-03-19 | 2010-06-30 | 富山化学工業株式会社 | 5−デオキシ−5−アルカノイルアミノ−β−D−アロフラノシルウロン酸誘導体またはその塩、それらを含有する抗真菌剤及びキチン合成酵素阻害剤 |
EP1194436B1 (en) | 1999-07-06 | 2005-11-30 | Methylgene, Inc. | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase |
MXPA02001394A (es) * | 1999-08-10 | 2002-08-12 | British Biotech Pharm | Agentes antibacterianos. |
FR2812635B1 (fr) * | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
CA2429346A1 (en) | 2000-11-16 | 2002-05-23 | Sankyo Company, Limited | 1-methylcarbapenem derivatives |
JP2002212182A (ja) * | 2000-11-16 | 2002-07-31 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体 |
FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
JP2004043438A (ja) | 2002-05-15 | 2004-02-12 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体を含有する医薬 |
US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
CA2531728A1 (en) * | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
WO2005033129A1 (de) | 2003-10-01 | 2005-04-14 | Bayer Healthcare Ag | Antibakterielle amid-makrozyklen |
EP1751527A2 (en) | 2004-02-24 | 2007-02-14 | SSCI, Inc. | Analysis and screening of solid forms using the atomic pair distribution function |
KR101403164B1 (ko) * | 2005-12-07 | 2014-06-03 | 바실리어 파마슈티카 아게 | 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합 |
AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
RS53862B1 (en) * | 2008-01-18 | 2015-08-31 | Merck Sharp & Dohme Corp. | INHIBITOR BETA-LACTAMASE |
-
2009
- 2009-01-15 RS RS20150154A patent/RS53862B1/en unknown
- 2009-01-15 DK DK09701487.2T patent/DK2231667T3/da active
- 2009-01-15 PT PT97014872T patent/PT2231667E/pt unknown
- 2009-01-15 MY MYPI2010003255A patent/MY162532A/en unknown
- 2009-01-15 PT PT131809691T patent/PT2666774E/pt unknown
- 2009-01-15 JP JP2010543219A patent/JP5038509B2/ja active Active
- 2009-01-15 AU AU2009206119A patent/AU2009206119C1/en active Active
- 2009-01-15 SI SI200931147T patent/SI2666774T1/sl unknown
- 2009-01-15 US US12/812,763 patent/US8487093B2/en active Active
- 2009-01-15 EP EP09701487.2A patent/EP2231667B1/en active Active
- 2009-01-15 RU RU2010134425/04A patent/RU2445314C9/ru active
- 2009-01-15 KR KR1020167021668A patent/KR101800610B1/ko active IP Right Grant
- 2009-01-15 SI SI200930777T patent/SI2231667T1/sl unknown
- 2009-01-15 CN CN200980102425.0A patent/CN101918407B/zh active Active
- 2009-01-15 WO PCT/US2009/031047 patent/WO2009091856A2/en active Application Filing
- 2009-01-15 CN CN201210277503.4A patent/CN102827067B/zh active Active
- 2009-01-15 ME MEP-2013-511A patent/ME02089B/me unknown
- 2009-01-15 MX MX2010007823A patent/MX2010007823A/es active IP Right Grant
- 2009-01-15 KR KR1020107015963A patent/KR101648728B1/ko active IP Right Grant
- 2009-01-15 RS RS20130511A patent/RS53052B/en unknown
- 2009-01-15 PL PL13180969T patent/PL2666774T3/pl unknown
- 2009-01-15 BR BRPI0906871-6A patent/BRPI0906871B1/pt active IP Right Grant
- 2009-01-15 ES ES09701487T patent/ES2433744T3/es active Active
- 2009-01-15 NZ NZ586861A patent/NZ586861A/en unknown
- 2009-01-15 CA CA2712783A patent/CA2712783C/en active Active
- 2009-01-15 UA UAA201010164A patent/UA101966C2/ru unknown
- 2009-01-15 ES ES13180969.1T patent/ES2533826T3/es active Active
- 2009-01-15 EP EP13180969.1A patent/EP2666774B1/en active Active
- 2009-01-15 DK DK13180969.1T patent/DK2666774T3/en active
- 2009-01-15 PL PL09701487T patent/PL2231667T3/pl unknown
-
2010
- 2010-06-15 IL IL206395A patent/IL206395A/en active IP Right Grant
- 2010-06-30 NI NI201000115A patent/NI201000115A/es unknown
- 2010-07-12 HN HN2010001395A patent/HN2010001395A/es unknown
- 2010-07-15 EC EC2010010345A patent/ECSP10010345A/es unknown
- 2010-07-16 MA MA33026A patent/MA32025B1/fr unknown
- 2010-07-16 DO DO2010000218A patent/DOP2010000218A/es unknown
- 2010-07-21 CO CO10088709A patent/CO6331438A2/es active IP Right Grant
- 2010-07-27 ZA ZA2010/05333A patent/ZA201005333B/en unknown
- 2010-08-10 CR CR11626A patent/CR11626A/es unknown
- 2010-10-26 EC EC2010010568A patent/ECSP10010568A/es unknown
- 2010-11-03 HK HK10110297.7A patent/HK1143809A1/xx unknown
-
2011
- 2011-05-26 JP JP2011118249A patent/JP5597164B2/ja active Active
-
2012
- 2012-05-22 JP JP2012116243A patent/JP5422020B2/ja active Active
-
2013
- 2013-06-06 US US13/911,549 patent/US20130274475A1/en not_active Abandoned
- 2013-11-25 HR HRP20131123AT patent/HRP20131123T1/hr unknown
- 2013-12-03 CY CY20131101079T patent/CY1114900T1/el unknown
- 2013-12-07 HK HK13113644.8A patent/HK1186180A1/xx unknown
-
2015
- 2015-03-10 HR HRP20150269TT patent/HRP20150269T1/hr unknown
- 2015-03-23 CY CY20151100288T patent/CY1116243T1/el unknown
-
2020
- 2020-06-25 NL NL301051C patent/NL301051I2/nl unknown
- 2020-06-25 NL NL301050C patent/NL301050I2/nl unknown
- 2020-06-30 LU LU00165C patent/LUC00165I2/fr unknown
- 2020-07-03 LT LTPA2020517C patent/LTPA2020517I1/lt unknown
- 2020-07-03 LT LTPA2020516C patent/LTC2231667I2/lt unknown
- 2020-07-03 LT LTPA2020518C patent/LTC2666774I2/lt unknown
- 2020-07-09 HU HUS2000024C patent/HUS000504I2/hu unknown
- 2020-07-09 HU HUS2000023C patent/HUS000513I2/hu unknown
- 2020-07-10 FR FR20C1031C patent/FR20C1031I2/fr active Active
- 2020-07-10 FR FR20C1030C patent/FR20C1030I2/fr active Active
- 2020-07-10 FR FR20C1032C patent/FR20C1032I2/fr active Active
- 2020-07-15 CY CY2020024C patent/CY2020024I1/el unknown
- 2020-07-15 CY CY2020025C patent/CY2020025I2/el unknown
- 2020-07-15 CY CY2020023C patent/CY2020023I2/el unknown
- 2020-08-10 NO NO2020024C patent/NO2020024I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS000504I2 (hu) | Relebaktám, adott esetben monohidrát formájában, és imipenem kombinációja | |
HK1243713A1 (zh) | 一種化合物的固體形式及其使用方法 | |
HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (en) | Compounds and methods of use | |
ZA201100372B (en) | Wounddressing and headgear | |
GB0818241D0 (en) | Compounds and their use | |
HK1160725A1 (en) | Carbonate prodrugs and methods of using the same | |
IL208081A0 (en) | Amido - thiophene compounds and their use | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
ZA201007395B (en) | Aryl-quinolyl compounds and their use | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
SI2344449T1 (sl) | Aril-fenil-sulfonamido-cikloalkilne spojine in njihova uporaba | |
HK1167592A1 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
GB0922510D0 (en) | Compound and use | |
TWI367210B (en) | Estrogenic-active compounds and application thereof | |
GB0801319D0 (en) | Compounds and their use | |
GB0813359D0 (en) | Halfin and/or platerfin | |
GB0802194D0 (en) | Compounds and their use | |
GB0817897D0 (en) | Compounds and their use | |
GB0813254D0 (en) | Compounds and their use | |
HU0800405D0 (en) | Ewnvironment-friendly biocidis and use thereof | |
HU0800656D0 (en) | Effective use of tea-composition |